Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
Delayed Quote. Delayed Nasdaq - 07/06 04:00:00 pm
20.93 USD   -2.42%
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/05Correction to Poor Performance of Health-Care Stocks Article
DJ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Inovio Pharmaceuticals, Inc. (INO)

share with twitter share with LinkedIn share with facebook
05/26/2020 | 05:39pm EDT

Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.

If you suffered a loss as a result of Inovio's misconduct, click here.

Inovio Pharmaceuticals, Inc. (INO) Accused of False COVID-19 Vaccine Claims

According to the pending class action lawsuit filed against Inovio, on March 11, 2020, the World Health Organization ("WHO") declared the coronavirus COVID-19 outbreak a global "pandemic" due to its extraordinary "speed and scale of transmission." In response to mounting public concern, on February 14, 2020, Inovio's CEO announced on national news that the Company had developed a COVID-19 vaccine "in a matter of about three hours" and re-affirmed this statement two weeks later in a well-publicized meeting with President Trump. As a result, Inovio's stock price more than quadrupled. However, contrary to these claims, on March 9, 2020, Citron Research exposed Inovio's misstatements, calling for an SEC investigation into Inovio's "dangerous claim that they designed a [COVID-19] vaccine in 3 hours." Consequently, Inovio admitted the Company had not developed a COVID-19 vaccine but rather a "vaccine construct." On this news, Inovio's stock price declined to a mere $5.70 per share, representing a 71% decline from the Company's class period high of $19.36 per share.

Inovio Pharmaceuticals, Inc. (INO) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Inovio settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news on INOVIO PHARMACEUTICALS, IN
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/05Correction to Poor Performance of Health-Care Stocks Article
DJ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/03INOVIO PHARMACEUTICALS : Wall Street shifts bets to big pharma as COVID-19 vacci..
RE
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
07/01China's Sinopharm unit completes new COVID-19 vaccine plant, doubles capacity
RE
06/30Health Care Up As Sector Seen As Resilient In Covid Era -- Health Care Roundu..
DJ
06/30Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters
RE
06/30INOVIO PHARMACEUTICALS : Announces Positive Interim Phase 1 Data For INO-4800 Va..
PR
06/25INOVIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regul..
AQ
More news
Financials (USD)
Sales 2020 13,6 M - -
Net income 2020 -111 M - -
Net Debt 2020 - - -
P/E ratio 2020 -29,9x
Yield 2020 -
Capitalization 3 309 M 3 309 M -
EV / Sales 2019
Capi. / Sales 2020 244x
Nbr of Employees 190
Free-Float 97,5%
Chart INOVIO PHARMACEUTICALS, IN
Duration : Period :
Inovio Pharmaceuticals, In Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, IN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 20,86 $
Last Close Price 20,93 $
Spread / Highest target 115%
Spread / Average Target -0,35%
Spread / Lowest Target -61,8%
EPS Revisions
Managers
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOVIO PHARMACEUTICALS, INC.534.24%3 309
LONZA GROUP45.13%40 295
CELLTRION, INC.68.78%34 505
SEATTLE GENETICS, INC.49.18%29 259
IQVIA HOLDINGS INC.-7.04%27 025
INCYTE CORPORATION21.93%23 144